JNSS 2010, 1(3-4):126-135 | DOI: 10.32725/jnss.2010.014

PREDICTION OF PERSONAL HEALTH RISK FACTORS IN METABOLIC SYNDROME

Claus Muss1,*, Selvaraj Y. Subramaniam2
1 International Scientific Society of Applied Preventive Medicine (I-GAP), Private Clinics and I-GAP Research Laboratories, Vienna, Austria
2 USCI University, Kuala Lumpur, Malaysia

In European health systems the metabolic syndrome has become of major concern in public health. The same tendency has been observed also in developing countries of South East Asia. The metabolic syndrome is an important health risk factor often related to Diabetes and cardiovascular disease. A successful approach to the prevention of the metabolic syndrome therefore contributes to the stabilization of the present and future health system of the European Union and specific parts of Asia decisively. Practical guidelines for the prevention of diabetes and metabolic syndrome are needed urgently. Laboratory diagnostics provide a practicable tool in the early diagnosis of the metabolic syndrome. In this article new laboratory markers such as Adiponectin, Proinsulin and Asymmetric Dimethylarginine (ADMA) are discussed as markers of metabolic risk.

Keywords: metabolic syndrome; diabetes; Adiponectin, Proinsulin, Asymmetric Dimethylarginine (ADMA)

Received: September 20, 2010; Accepted: November 18, 2010; Published: September 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Muss C, Subramaniam SY. PREDICTION OF PERSONAL HEALTH RISK FACTORS IN METABOLIC SYNDROME. Journal of Nursing, Social Studies, Public Health and Rehabilitation. 2010;1(3-4):126-135. doi: 10.32725/jnss.2010.014.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Böger RH (2003). The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 59: 824-828. Go to original source... Go to PubMed...
    2. Böger RH, Bode-Böger SM, Szuba A, Tangphao O, Tsao PS, Chan JR, Blaschke TF, Cooke JP (1998). Asymmetric dimethylarginine: A novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation. 98: 1842-1847. Go to original source... Go to PubMed...
    3. Deveci E, Yesil M, Akinci B, Yesil S, Postaci N, Arikan E, Koseoglu M (2009). Evaluation of insulin resistance in normoglycemic patients with coronary artery disease. Clin Cardiol. 32(1): 32-36. Go to original source... Go to PubMed...
    4. Díez JJ, Iglesias P (2003). The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 148(3): 293-300. Go to original source... Go to PubMed...
    5. Forst T, Pfützner A (2006). Current laboratory parameters in the differential diagnosis of type 2 diabetes mellitus. Proinsulin, adiponectin and others. Dtsch Med Wochenschr. Dec 131 Suppl. 8: S268-S273. Go to original source... Go to PubMed...
    6. Gallagher D (1996). How useful is BMI for comparison of body fatness across age, sex and ethnic groups? American Journal of Epidemiology. (143) 228-239. Go to original source... Go to PubMed...
    7. Garrow JS, Webster J (1985). Quetelet's index (W/H2) as a measure of fatness. International Journal of Obesity. 9: 147-153.
    8. Kennedy A, Martinez K, Chuang C-C, LaPoint K, McIntosh M (2009). Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. J Nutr. 139(1): 1-4. Go to original source... Go to PubMed...
    9. Kielstein JT, Böger RH, Bode-Böger SM et al. (1999). Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 10: 594-600. Go to original source... Go to PubMed...
    10. Lakka H-M et al. (2002). The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men JAMA. 288: 2709-2716. Go to original source... Go to PubMed...
    11. Lara-Castro C, Fu Y, Chung BH, Garvey WT (2007). Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 18(3): 263-270. Go to original source... Go to PubMed...
    12. Li H, Lelliott C, Håkansson P, Ploj K, Tuneld A, Verolin-Johansson M, Benthem L, Carlsson B, Storlien L, Michaëlsson E (2008). Intestinal, adipose, and liver inflammation in diet-induced obese mice. Metabolism. 57(12): 1704-1710. Go to original source... Go to PubMed...
    13. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC (2003). Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 24: 1912-1919. Go to original source... Go to PubMed...
    14. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I (2004). Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 24(1): 29-33. Go to original source... Go to PubMed...
    15. Mei Z, Grummer-Strawn LM, Pietrobelli A, Goulding A, Goran MI, Dietz WH (2002). Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents. American Journal of Clinical Nutrition, p. 7597-7985. Go to original source... Go to PubMed...
    16. Miller M (2007). Insulin resistance. Aktuel Ernähr Med. 7(32): 167-174. Go to original source...
    17. Nijveldt RJ, Teerlink T, Van der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA (2003). Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr. 22: 23-30. Go to original source... Go to PubMed...
    18. Pfützner A, Pfützner AH, Larbig M, Forst T (2004). Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther. 6(3): 405-412. Go to original source... Go to PubMed...
    19. Pfützner A, Schöndorf T, Seidel D, Winkler K, Matthaei S, Hamann A, Forst T (2006). Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism. 55(1): 20-25. Go to original source... Go to PubMed...
    20. Prentice AM, Jebb SA (2001). Beyond Body Mass Index. Obesity Reviews. 2(3): 141-147. Go to original source... Go to PubMed...
    21. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH (2003). Endothelial dysfunction and raised plasma concentrations of asymmetricdimethylarginine in pregnant women who subsequently develop preeclampsia. Lancet. 361: 1511-1517. Go to original source... Go to PubMed...
    22. Stühlinger M, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS (2002). Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc. 287: 1420-1426. Go to original source... Go to PubMed...
    23. Thorens B (2008). Glucose sensing and the pathogenesis of obesity and type 2 diabetes. Int J Obes (Lond). 32 Suppl. 6: S62-S71. Go to original source... Go to PubMed...
    24. Ukkola O, Santaniemi M (2003). Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med. 80(11): 696-702. Go to original source... Go to PubMed...
    25. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992). Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet. 339: 572-575. Go to original source... Go to PubMed...
    26. Vasseur F, Meyre D, Froguel P (2007). Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies. Expert reviews in molecular medicine. 8(27): 1-12. Go to original source... Go to PubMed...
    27. Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich JC, Böger RH (2001). Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet. 358: 2113-2117. Go to original source... Go to PubMed...
    28. 40. EASD-Jahreskongress (2004), European Diabetes-Society, Munich.

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content